Mazdutide vs Retatrutide: 2026 Trial Results, FDA Status, and Who Can Get Them

By The RX Index Editorial Team · Last verified October 2026

Mazdutide vs retatrutide: Lilly reported 28.3% weight loss over 80 weeks with retatrutide 12 mg; Innovent reported 18.55% over 60 weeks with mazdutide 9 mg. These separate trials don’t prove which works better. Neither drug is FDA-approved. Mazdutide is approved in China; retatrutide is investigational, with access through trials or a narrow doctor-requested expanded-access program.

Two things change that picture. First, the main journal results are 25.0% and 16.65%—not the company headlines above. Subtracting placebo still cannot make these separate trials a fair comparison. Second, the diabetes results need their own look. Trial reports and GLORY-2 show why.

And the idea that mazdutide is the "gentler" one? In GLORY-2’s 9 mg group, about half the people reported vomiting. Here’s what’s really behind each number.

RX Index Decision Verdict: Neither drug is a regular U.S. prescription option today. Compare the evidence, then decide with your clinician whether to review an approved option now or ask about a trial or expanded access.

• Best for: Adults who keep seeing both names and want the evidence and the access facts in one place, or who are getting ready to talk with a clinician.
• Not ideal for: Anyone looking for a dose, a way to combine either drug with what they take now, or a place to buy a vial for personal use. Neither is an FDA-approved U.S. pharmacy product.
• The factor that matters most: Whether you can actually get the drug legally and safely, not which headline number is bigger.

Mazdutide vs retatrutide at a glance

Mazdutide turns on two hormone receptors: GLP-1 and glucagon. Retatrutide turns on three: GLP-1, GIP, and glucagon. That difference explains the names. It doesn't tell you which drug works better or causes fewer side effects.

A quick word on the terms. A receptor is a lock on your cells that a hormone fits into to send a signal. An agonist is a drug that turns that lock on.

• GLP-1 (glucagon-like peptide-1) tells your brain you're full.
• GIP (glucose-dependent insulinotropic polypeptide) helps with blood sugar and seems to work alongside GLP-1.
• Glucagon affects blood sugar and energy use. Researchers are testing whether adding this target helps with weight loss and liver fat. The ADA’s research-session report explains the idea.

Sources: Innovent weight-management approval; diabetes approval; 2019 licensing agreement; Lilly, September 29, 2026; Lilly expanded access; TRIUMPH-5 registry; Innovent, June 8, 2026; ADA, 2023. Checked October 15, 2026. BMI means body mass index, a measure based on weight and height—not a full health assessment.

"Dual" and "triple" count receptor targets, not medicines. Each drug is a single molecule, not a mix of two or three drugs. And more targets don't automatically mean more weight loss. We show why in our guide to triple vs dual agonist weight loss.

What's behind each weight-loss number

In separate main trials, retatrutide 12 mg lowered weight 25.0% over 80 weeks and mazdutide 9 mg lowered weight 16.65% over 60 weeks. Those are the main results in the published journal papers. The companies' own headline numbers are higher: 28.3% and 18.55%. The trials studied different people for different lengths of time, so neither set of numbers can crown a winner.

Think of it like two runners on two different courses. One ran 80 weeks, one ran 60. The terrain wasn't the same either. You can see who went farther. You can't say who's faster.

Separate studies, not a head-to-head trial. Research doses identify study groups. They are not doses to take.

Here's what the table tells us, and what it doesn't.

Retatrutide’s reported average was larger. But the table does not measure how much better one drug works than the other. The last row gives each paper’s own placebo comparison; rounding means it need not equal a subtraction of the displayed averages. Subtracting those two differences still does not turn separate trials into one fair race.

Compare percent, not pounds. Retatrutide's trial started with people about 40 pounds heavier on average. The same percent means more pounds for them, so pound totals make the gap look bigger than it is.

Two numbers you'll see online that don't belong in this race:

• Mazdutide’s "20.08%" comes only from GLORY-2 participants without type 2 diabetes. That’s a slice of the trial, not the whole trial (Innovent).
• Retatrutide’s "30.3%" is the 104-week result for the original 12 mg group within a selected extension—not all 532 extension participants. Entry required a starting BMI of at least 35, a BMI above 22 at week 80, and completing 80 weeks without stopping treatment or permanently lowering the dose. It isn’t the whole trial’s result (Lilly).

Looking for a treatment you can actually start? The right path depends on your state, your insurance and its list of covered drugs, your budget, and whether you want a pill or a shot. The RX Index’s Find My GLP-1 Path tool is free, takes about 2 minutes, and needs no signup. Answer a few quick questions to see suggested paths and providers for your goals, budget, and situation. It does not confirm insurance coverage or arrange access to either investigational drug.

See which current treatment paths fit you

Why do the numbers change from one source to the next?

A weight-loss percentage only makes sense with four things attached: which study, which people, how many weeks, and which way the math was done. Change any one of them and the number changes, even when no one is wrong.

The "way the math was done" part has a name: the estimand. It's the exact question a study's numbers answer.

• Continued-treatment estimate (efficacy estimand): what would happen if people kept taking the drug as planned.
• Estimate including treatment stops (treatment-regimen estimand): asks about the assigned treatment even when people stop it. Missing measurements still need statistical estimates.

Neither one is "the real number." Neither one predicts what you personally will lose. Lilly labels its two retatrutide numbers this way. The GLORY-2 abstract and Innovent release we read don’t name the estimands behind their different mazdutide results, so we haven’t put a label on them. That limit does not apply to the full U.S. mazdutide paper below. More on reading these numbers: how to read GLP-1 clinical trials and placebo-adjusted weight loss, explained.

What Lilly's U.S. mazdutide study adds

Lilly ran its own mazdutide trial in 179 U.S. adults without diabetes, published August 21, 2026. Its main result was at 32 weeks: 7.3% in the low-dose group, 15.6% with 10 mg, and 18.1% with 16 mg, compared with 0.9% on placebo. The low-dose group was at 3 mg at that endpoint; the paper calls it the 3–6 mg group because its dose increased later (Lancet Diabetes & Endocrinology00160-9)). The 48-week results, a secondary measure, show why the biggest number isn’t the whole story.

Source: Hsia et al., Lancet Diabetes & Endocrinology, August 21, 202600160-9) (full-paper copy, Tables 2–4). The 48-week results are secondary. The 32-week result was the main measure. Safety percentages use participants who received treatment; stopping the drug is not the same as leaving the study.

Look at the 16 mg row. It had the biggest continued-treatment estimate. But the estimate that included treatment stops came in below the 10 mg group. One in five people in the 16 mg safety group stopped the drug because of side effects. The analysis also filled in missing measurements using assumptions based on placebo data. This is not proof that 10 mg works better for an individual. It is why a single headline percentage can’t settle mazdutide vs retatrutide.

Is mazdutide really gentler than retatrutide?

Both drugs’ most common reported side effects were stomach and gut problems: nausea, vomiting, and diarrhea. The mazdutide 9 mg trial reported a higher vomiting rate than the retatrutide 12 mg trial, but a lower rate of stopping treatment. These were separate trials, so neither drug can be called safer from this comparison.

Sources: GLORY-2, JAMA; TRIUMPH-1, Lilly. Rates from each study’s own groups. This is not a head-to-head safety comparison.

So "gentler" is the wrong word. "Fewer people quit, in that one trial" is closer to what the data shows. Feeling sick and stopping the drug are two different things. A trial can have lots of the first and little of the second.

Why the difference? These reports do not establish the reason. The trials ran in different countries, with different people and different dose plans. We’re not going to guess.

Three more things worth knowing:

• Dysesthesia is a strange skin feeling, like tingling, burning, or skin that feels sunburned when nothing touched it. Lilly says most cases were mild to moderate and most went away during treatment. More detail is in our guide to retatrutide side effects.
• Higher mazdutide doses also need a look at tolerability. In Lilly’s U.S. study, 20% stopped the 16 mg dose because of side effects, mostly stomach problems.
• Neither drug has an FDA-approved label yet. That does not mean there are no safety rules: trials and expanded access have screening and monitoring requirements. Rare and long-term risks still need study; these results do not settle which drug is safer. Lilly’s access policy describes some of those safeguards.

If you’re using a weight-loss shot and have severe belly pain that won’t go away or can’t keep fluids down, get urgent medical help. Trouble breathing, collapse, or being unable to wake someone calls for 911. See the Zepbound Medication Guide and Poison Control’s emergency guidance.

Which results apply if you have type 2 diabetes?

Both drugs lowered weight and blood sugar in studies of people with type 2 diabetes. The big 28.3% retatrutide headline came from a trial that left out people with diabetes, so it isn’t the number to look at if you have it. The diabetes studies below reported lower weight-loss averages, but their different drugs, doses, and designs do not isolate the effect of having diabetes.

Sources: Lilly TRIUMPH-2, September 29, 2026; Innovent DREAMS-3, October 26, 2025 and June 8, 2026 update; DREAMS-3 registry. A1C reflects average blood sugar over about three months; changes above are percentage points. These are separate trials, not a comparison between mazdutide and retatrutide.

Mazdutide has a finished comparison against an approved drug. In DREAMS-3, 48.0% of people on mazdutide reached both an A1C under 7% and 10% or more weight loss, compared with 21.0% on semaglutide. In that open-label trial, everyone knew which drug they were taking. Retatrutide also has active-comparator evidence: a 2023 Phase 2 diabetes trial included dulaglutide 1.5 mg (ADA’s trial presentation report). Its Phase 3 comparison against tirzepatide has not posted results in the registry. Approved options for diabetes are in our guide to the best GLP-1 for diabetes.

Can you get mazdutide or retatrutide in the U.S.?

Not as a regular prescription. Lilly describes retatrutide access through clinical trials or a narrow expanded-access program your doctor must request. For mazdutide, we identified clinical research but no public U.S. expanded-access program. FDA specifically says retatrutide cannot be compounded under federal law; a mazdutide seller’s “compounded” label is not proof of a lawful treatment pathway.

Sources: FDA, content current October 1, 2026; FDA’s mazdutide seller warning; FDA’s 503A bulk-substance rules; Lilly Medical, reviewed August 26, 2026. Checked October 15, 2026.

China approval isn't U.S. approval

China’s drug regulator, the NMPA, approved mazdutide for adult weight management, announced in June 2025. The U.S. Food and Drug Administration (FDA) makes its own decisions, and it hasn’t approved mazdutide. A Chinese approval also doesn’t make a vial from an online seller the real, approved medicine. Innovent applied in China for a higher 9 mg dose in November 2025. Its June 8, 2026 report still described that application as awaiting approval; we did not find a later decision announcement in the sources searched October 15, 2026 (Innovent).

Who can get retatrutide through expanded access?

Lilly describes expanded access as a rare exception for people who can't join a trial and have run out of other options. It is not a sign-up program. According to Lilly's policy, a patient must meet all of these:

1. Age 18 or older.
2. BMI of 35 or higher despite sticking with, and tolerating, the highest available dose of a weight-management medicine.
3. Two or more serious or life-threatening health problems caused by obesity, already being treated.
4. Unable to join a retatrutide trial or a similar one, because they don't qualify or no enrolling site is reasonably close.
5. Every standard option, including bariatric surgery, already discussed with them.

People with a medical reason not to take retatrutide are excluded. Even when all five boxes are checked, it isn't simple.

• Only your doctor can ask. Lilly tells patients not to call Lilly directly.
• Your doctor takes on real paperwork. They must sign an agreement, apply to the FDA as sponsor of an individual-patient expanded-access request, get approval from an ethics board, and store and track the drug.
• Lilly doesn't ship to patients. Supply and geography also limit access.
• The drug itself is provided at no cost. That doesn't mean the doctor visits and tests are free.

Say you’re 58, your BMI is 42 after a year on the top dose of Zepbound, and you have heart failure and sleep apnea. That could be a reason to ask the doctor treating your weight about the criteria—not proof you qualify. Your doctor would still need to check all five requirements, contraindications, and whether a trial is an option. Lilly then reviews the request case by case. There are other paths below. More in our guide to retatrutide availability.

What about the vials sold online?

FDA says it has warned companies that sold semaglutide, tirzepatide, retatrutide, survodutide, or mazdutide falsely labeled "for research purposes" or "not for human consumption," with dosing instructions, to people. FDA calls these products of unknown quality and urges people not to buy them (FDA).

“Research use only” is not proof that a vial is suitable for people. The label does not establish what is in it, the amount, or its quality. A price on a seller’s website is not an approved U.S. prescription price; neither drug has a verified U.S. retail price. If you used one and feel unwell, call Poison Control at 1-800-222-1222. If someone collapses, has a seizure, can’t breathe, or can’t be woken, call 911 (Poison Control). How to spot fakes: avoiding fake GLP-1 medications online.

If what you really want is treatment that's legal and available now, the question changes. It becomes which approved option fits your insurance and budget.

Compare treatment paths for your budget

When could mazdutide or retatrutide reach U.S. pharmacies?

No U.S. pharmacy launch date is confirmed for either one. Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027. We did not identify a mazdutide FDA filing announcement in the sources checked October 15, 2026.

Retatrutide: applying isn’t approval. Lilly plans a biologics license application, or BLA. For an original BLA under the usual FDA review goals, the agency first has a 60-day filing review. The standard goal is then action on 90% of applications within 10 months of that filing date; the priority-review goal is 6 months. These are performance goals, not an approval promise, and retatrutide’s review pathway is not confirmed. A planned application in early 2027 does not mean approval in spring 2027. Sources: Lilly’s filing plan and FDA review goals. Our guide to the FDA approval process for obesity medicines walks through each step.

Mazdutide: Lilly has published U.S. data (the study above). We did not identify a U.S. Phase 3 trial or FDA filing announcement in the records and company sources checked. Lilly’s public pipeline page, with data dated August 5, 2026, did not list mazdutide when we checked. But it also says some molecules are not identified for competitive reasons. That doesn’t mean Lilly dropped it. There is no confirmed U.S. launch timeline in these sources. A Phase 3 announcement or regulatory filing would be a meaningful next sign (Lilly pipeline; U.S. trial search).

Two studies worth watching:

• TRIUMPH-5, retatrutide vs tirzepatide with an estimated enrollment of 800 adults, lists estimated primary completion in November 2026 and study completion in December 2026. The record is active, not recruiting, with no results posted; its last update was July 20, 2026. A completion estimate is not a results-release date (ClinicalTrials.gov).
• Innovent's high-dose mazdutide vs tirzepatide trial is underway in China (Innovent).

Notice the pattern. Both newcomers are being measured against tirzepatide, the drug in Zepbound and Mounjaro. It's the yardstick, and it's available now.

Should you wait, or start a treatment now?

Waiting for a future drug does not have to mean going without care now. No direct mazdutide–retatrutide comparison shows that waiting would give you a better result. FDA-approved medicines like Zepbound (tirzepatide) and Wegovy (semaglutide) are options to discuss with a clinician today. Keep reviewing any current treatment with your prescriber rather than changing it because of a headline.

No web page, including this one, can tell you whether a future drug would work better for you. A licensed clinician decides what fits your health history. What we can do is help you figure out which next step matches where you are.

Hit a plateau? That's a reason to ask for a treatment review, not proof you need an investigational drug. Don't add mazdutide or retatrutide to tirzepatide on your own. No study here tested that combination for safety or benefit.

A few quick questions can sort out your next step:

1. Do you want to learn about these drugs, or start treatment soon?
2. Do you know your BMI and any weight-related conditions? A BMI of 30 or higher, or 27 or higher with a condition such as high blood pressure, matches common adult weight-management trial criteria—not automatic approval for treatment. (Check the BMI chart.)
3. Do you know whether your plan covers weight-loss medicines?

If you don’t know the answer to number 3, that’s normal. Your plan’s member portal or pharmacy-benefits number can help. The RX Index tool suggests paths; it does not verify coverage. Ro offers a separate coverage check for certain medicines, described below.

If you’ve decided to explore an approved medicine now, Ro is one option for adults who want online care and commercial-insurance help. Ro-affiliated clinicians prescribe Zepbound (tirzepatide) and other FDA-approved GLP-1 medicines when appropriate. Ro also offers a separate free insurance check for Ozempic pens, Wegovy pens, and Zepbound single-dose autoinjector pens—not the Zepbound KwikPen, Wegovy pill, or Foundayo pill. Its coverage checker contacts your insurer and sends a report; it does not write a prescription or submit a treatment request. Prior-authorization paperwork is part of its care program. Prior authorization is a permission slip your insurer requires before it will pay.

Ro does not advertise mazdutide or retatrutide as treatment options. The formal trial and expanded-access paths above are separate from ordinary telehealth care. An approved medicine still requires an individual prescription; neither eligibility nor a start date is guaranteed.

Here's what Ro lists as of October 15, 2026 (Ro pricing):

• Membership: $39 for the first month, refunded if you’re not eligible for a GLP-1. After that, $74 to $149 a month depending on the plan. The $74 rate requires a 12-month plan paid upfront, which is $888 at once after the introductory month—not a $74 monthly bill. The month-to-month plan is $149 per month. Cancel before renewal to avoid a new billing period; Ro’s terms make paid membership fees non-refundable outside the stated onboarding exception.
• Medication is a separate charge. Ro lists Zepbound KwikPen cash prices of $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5–15 mg with the manufacturer offer. Each pen covers 28 days, not a calendar month. Lilly’s offer covers the first eligible higher-dose fill; continued $449 pricing requires buying the next refill within 45 days of delivery of the prior one. Without that offer, Lilly lists regular prices of $499 for 7.5 mg and $699 for 10–15 mg. That is Lilly’s published ladder, not a verified Ro checkout total (Lilly’s terms).
• Introductory cash example, 2.5 mg: $39 membership + $299 for the first 28-day medication supply = $338 subtotal. It is not a recurring monthly total or a charge everyone owes today. Ro says billing depends on treatment eligibility and the chosen plan. We did not verify a completed checkout, so needles, shipping, any taxes, and other extra charges are not assumed to be zero. Insurance can lower the cost of a covered formulation, but coverage isn’t guaranteed; this cash-pay KwikPen offer is separate from the pen coverage check.

Ro lists ongoing care, insurance support, and lab testing when needed among the membership services. Its terms include 24 consults per year, charge $15 for each additional consult, and allow separate charges for additional lab tests. Do not assume extra tests are covered by the advertised price (Ro terms).

Have Medicare or Medicaid? Start with your plan and your treating clinician rather than this commercial-insurance path. Already have a prescriber? You can also ask that office to check coverage without adding a telehealth membership.

Need help checking your commercial coverage? Start with Ro’s free report; you do not need to commit to treatment to get it:

Check your Zepbound coverage with Ro

Still deciding between Zepbound, Wegovy, or a pill like Foundayo? Not sure which one your budget or plan can handle? Start by finding a path that fits your budget and preferences.

See which GLP-1 path fits you

What we actually verified

We checked the trial reports, company announcements, regulator pages, and Lilly’s expanded-access policy listed below on October 15, 2026. We did not test either drug, and we don’t recommend buying either one from a research-vial seller. A source’s publish date and the date we checked it are listed separately.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

This page uses an RX Index Decision Verdict, not a numerical medication rating. Our methodology explains how we assess providers and treatment paths.

What we couldn't confirm:

• Whether any reader qualifies for a trial or expanded access.
• Which trial sites are enrolling near you.
• Any official U.S. price for either drug.
• An FDA approval date.
• China's decision on the 9 mg mazdutide dose.
• A head-to-head result between these two drugs.
• The complete GLORY-2 and TRIUMPH-1 manuscripts; those journal checks used the abstracts. We did read the full U.S. Phase 2 mazdutide paper.
• Your Ro checkout total, insurance approval, or how the site’s quiz would match you.

Ro’s prices are what Ro states on its own pricing page. We checked the published terms, but we didn’t buy a membership or submit anyone’s insurance or health information.

Frequently asked questions

Is mazdutide better than retatrutide?

No direct trial comparing the two was identified in the sources checked. Retatrutide had larger reported weight-loss averages in separate trials, while fewer people stopped mazdutide because of side effects in GLORY-2. Those trials had different people, lengths, and methods. In the U.S., neither is a regular prescription option; retatrutide has a narrow expanded-access exception.

Can I add mazdutide or retatrutide to tirzepatide if I've plateaued?

Don’t do this on your own. None of the studies here tested that combination, so this evidence cannot establish its safety or benefit. Ask your prescriber for a treatment review instead. A plateau has approved options to talk through.

Can you get retatrutide without being in a trial?

Lilly offers a narrow expanded-access path outside trials, requested by a treating doctor. A patient must meet all the criteria, including BMI of at least 35 despite sticking with and tolerating the highest available dose of weight-management therapy, plus two or more serious obesity-related complications receiving standard care. Meeting those criteria does not guarantee access: Lilly reviews each request, and supply and geography matter.

Is mazdutide the same as retatrutide?

No. They're different molecules. Mazdutide turns on two receptors (GLP-1 and glucagon). Retatrutide turns on three (it adds GIP).

Are mazdutide and retatrutide both made by Eli Lilly?

Both came from Lilly’s research. Innovent licensed mazdutide for development and sale in China in 2019; its Chinese approval announcements came in 2025, not 2019. Lilly also ran the U.S. mazdutide trial discussed above. Retatrutide is Lilly’s drug.

Does mazdutide's approval in China mean it's FDA-approved?

No. China's NMPA and the U.S. FDA make separate decisions, and the FDA hasn't approved mazdutide. A Chinese approval also doesn't make an online seller's vial the real medicine.

Are these pills or shots?

In the trials covered here, both were once-weekly shots under the skin. Nothing here shows that a pill, drop, or gum sold under either name works the same way.

When will retatrutide be FDA-approved?

No approval date is confirmed. Lilly plans to apply in the first quarter of 2027, but its review pathway and the FDA’s decision are not known. An exact launch date from a seller is not verified by that filing plan.

Can mazdutide or retatrutide be compounded?

FDA explicitly says retatrutide cannot be used in compounding under federal law. For mazdutide, FDA has warned sellers marketing it as an unapproved human drug; we did not verify a lawful routine compounding pathway. The legal test is not simply whether an FDA-approved brand exists—compounding has separate bulk-substance rules. Neither “compounded” nor “research use only” establishes an approved, safe treatment.

Should I wait instead of starting treatment now?

This comparison can’t show that waiting would give you a better result. Approved options exist today, and waiting for research does not require stopping or delaying appropriate care. Talk with your clinician about your health, your response so far, and your next step. Following new research and getting care now aren’t either-or.

Sources

1. Eli Lilly. Retatrutide TRIUMPH-1 results. May 21, 2026. Checked October 15, 2026.
2. Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). NEJM. Published online September 29, 2026. Abstract read. Checked October 15, 2026.
3. Eli Lilly. TRIUMPH-2 results and planned FDA submission. September 29, 2026. Issuer release distributed by PR Newswire. Checked October 15, 2026.
4. Gao L, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: GLORY-2. JAMA. Online June 7, 2026; print August 4, 2026; 336(5):377–388. Abstract read. Checked October 15, 2026.
5. Innovent Biologics. GLORY-2 results and 9 mg application update. June 8, 2026; discusses the November 2025 application. Checked October 15, 2026.
6. Innovent Biologics. Mazdutide approval announcement for chronic weight management in China. June 27, 2025. Checked October 15, 2026.
7. Innovent Biologics. DREAMS-3: mazdutide vs semaglutide. October 26, 2025. Checked October 15, 2026.
8. Innovent Biologics. DREAMS-3 update, including high-dose mazdutide vs tirzepatide research. June 8, 2026. Checked October 15, 2026.
9. Hsia SH, et al. Efficacy and safety of mazdutide in adults with obesity or overweight00160-9). Lancet Diabetes & Endocrinology. Published online August 21, 2026. Full published paper, public PDF copy. Checked October 15, 2026.
10. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current October 1, 2026. Checked October 15, 2026.
11. Lilly Medical. Is there an expanded access program for retatrutide? Last reviewed August 26, 2026. Checked October 15, 2026.
12. ClinicalTrials.gov. TRIUMPH-5, NCT06662383. Registry last updated July 20, 2026; estimated dates are month-level. Checked October 15, 2026.
13. Eli Lilly. Clinical Development Pipeline. Molecule and indication data as of August 5, 2026; interactive page inspected. Checked October 15, 2026.
14. Ro. Weight-loss program pricing. Current advertised membership and medication prices. Checked October 15, 2026.
15. Innovent Biologics. Mazdutide approval announcement for type 2 diabetes in China. September 19, 2025. Checked October 15, 2026.
16. ClinicalTrials.gov. DREAMS-3, NCT06184568. Registry last updated June 11, 2026; actual enrollment 349. Checked October 15, 2026.
17. ClinicalTrials.gov. Pre-approval expanded access, NCT07629401. Last updated August 6, 2026; mazdutide / LY3305677 U.S. study search. Checked October 15, 2026.
18. American Diabetes Association. Investigators’ Phase 2 retatrutide presentations, including the dulaglutide comparison. July 11, 2023. Associated trial DOI: 10.1016/S0140-6736(23)01053-X. Checked October 15, 2026.
19. U.S. Food and Drug Administration. Bulk drug substances used in compounding under section 503A; Summit Research Peptides warning letter, December 10, 2024. Checked October 15, 2026.
20. U.S. Food and Drug Administration. PDUFA VII performance goals, fiscal years 2023–2027. Original BLA review goals, page 4 of the PDF. Checked October 15, 2026.
21. Eli Lilly. Zepbound prescribing information and Medication Guide. Revised August 2026. Indications, safety warnings, clinical-study eligibility, and product presentations checked. Checked October 15, 2026.
22. National Capital Poison Center. First aid for poisonings. Emergency contacts and warning signs. Checked October 15, 2026.
23. Ro. Terms of Use (Ro Body membership, refunds, auto-renewal, consult and lab charges); GLP-1 Insurance Coverage Checker; Ro Body program. Checked October 15, 2026.
24. Eli Lilly. Zepbound savings and KwikPen self-pay offer terms. Current offer, eligibility, 28-day units, refill requirement, and regular-price ladder. Checked October 15, 2026.
25. Innovent Biologics and Eli Lilly. OXM3 / mazdutide licensing agreement. August 21, 2019. Checked October 15, 2026.
26. The RX Index. Find My GLP-1 Path. Landing page, metadata, and first unanswered question checked; no personal answers submitted. Checked October 15, 2026.
27. Novo Nordisk. Wegovy prescribing information. Revised June 2026. Approved weight-management indications and formulations checked. Checked October 15, 2026.